Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects
NCT ID: NCT00581191
Last Updated: 2009-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
72 participants
INTERVENTIONAL
2008-01-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
NCT00447681
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
NCT00409929
VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers
NCT02955459
Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects
NCT00434746
Safety and Tolerability of the First IV Dosing of SLV338 in Healthy Volunteers
NCT00885989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
0.5 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
2
1 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
3
2.5 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
4
5 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
5
10 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
6
15 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
7
20 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
8
30 mg SLV-351 (fasted)
SLV-351
SLV-351 capsules taken once
9
xx mg SLV-351 (fasted and fed)
SLV-351
SLV-351 capsules taken once
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SLV-351
SLV-351 capsules taken once
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women of nonchildbearing potential, aged 18-50 years.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wyeth
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3233A1-1000
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.